A federal class action lawsuit has alleged that Mylan, the pharmaceutical company behind EpiPen, conspired with major pharmacy benefit managers to inflate prices by more than 600% while systematically blocking cheaper epinephrine auto-injectors from reaching consumers. The scheme, first challenged in a 2017 RICO class action, allegedly involved Mylan paying excessive rebates to PBMs like CVS Caremark, Express Scripts, and UnitedHealth Group’s OptumRx in exchange for keeping EpiPen as the exclusive or preferred option on insurance formularies. The result was that millions of Americans with severe allergies — people who depend on epinephrine to survive anaphylactic reactions — were forced to pay wildly inflated prices for a device with no meaningful alternative on their insurance plan.
The litigation has since produced several major settlements, including a $264 million settlement between class plaintiffs and the Mylan defendants (Mylan N.V., Mylan Specialty L.P., Mylan Pharmaceuticals Inc., Viatris Inc., and former CEO Heather Bresch), a $345 million Pfizer settlement with the plaintiff class reached in November 2021, and a $73.5 million settlement with direct purchasers covering the class period from March 13, 2014 through February 6, 2025. State attorneys general in Indiana and Virginia have also secured their own settlements in 2026.
Table of Contents
- How Did Mylan Allegedly Conspire With PBMs to Block Cheaper EpiPen Competition?
- What Have Courts Actually Ruled in the EpiPen Antitrust Litigation?
- Breaking Down the Major EpiPen Settlements
- How to Check Your EpiPen Settlement Claim Status and Redeem Your Payment
- Why the EpiPen Price Increase Became a Symbol of Pharmaceutical Pricing Abuse
- State Attorney General Actions Signal Continued Enforcement Pressure
- What the EpiPen Litigation Means for Future Pharmaceutical Antitrust Cases
- Frequently Asked Questions
How Did Mylan Allegedly Conspire With PBMs to Block Cheaper EpiPen Competition?
The core of the class action rests on a straightforward but damaging allegation: Mylan deliberately inflated EpiPen’s list price and then used the gap between that list price and the net price — the so-called “spread” — as a financial incentive for PBMs. By marketing these inflated rebates to CVS Caremark, Express Scripts, and OptumRx, Mylan allegedly secured favorable formulary placement that kept EpiPen as the dominant or sole covered epinephrine auto-injector. For the PBMs, the arrangement was lucrative. Higher list prices meant larger rebate checks, which the PBMs could pocket or pass along selectively. For Mylan, it meant competitors offering cheaper alternatives simply could not get onto formularies, regardless of whether their products worked just as well. To understand why this matters, consider a parent whose child has a severe peanut allergy.
Their insurance formulary lists only EpiPen. A generic or competing auto-injector might cost a fraction of the price, but if it is not on the formulary, the family either pays full price out of pocket for the alternative or pays the inflated copay for EpiPen. The class action alleged that this was not a natural market outcome but a manufactured one, engineered through what plaintiffs characterized as kickback arrangements disguised as standard rebate negotiations. The distinction between a legitimate rebate and an anticompetitive kickback is central to the case. Rebates are common in pharmaceutical pricing and are not inherently illegal. But when rebates are structured specifically to exclude competition from the market — when the purpose is to lock out rivals rather than to reward volume — they cross into potential antitrust and RICO territory. That was the line plaintiffs argued Mylan had crossed.
What Have Courts Actually Ruled in the EpiPen Antitrust Litigation?
The legal path has not been entirely smooth for plaintiffs. A federal court dismissed the specific charge that Mylan prevented competition through its rebate arrangements with PBMs, which was a significant win for the defense. The court found that the particular theory connecting PBM rebates to anticompetitive exclusion did not survive scrutiny under the applicable legal standards. However, other antitrust claims in the case — including charges related to patent settlements — were allowed to proceed to trial. This meant the litigation continued even after that partial dismissal. This is an important nuance that consumers should understand.
A partial dismissal does not mean the plaintiffs lost or that the underlying conduct was found acceptable. It means one specific legal theory was rejected while others moved forward. In antitrust litigation, it is common for courts to narrow claims as cases progress, and the remaining claims were still substantial enough to push toward major settlements. The $264 million Mylan settlement and $345 million Pfizer settlement were reached in this context — not because every allegation was proven at trial, but because the remaining claims and the evidence supporting them created enough pressure to resolve the matter. However, if you are someone who believed the PBM rebate theory was the strongest part of the case, the dismissal of that particular charge is worth noting. It suggests that courts may be reluctant to treat PBM rebate arrangements as per se anticompetitive, even when the economic effects on consumers are severe. That has broader implications for pharmaceutical antitrust law beyond just EpiPen.
Breaking Down the Major EpiPen Settlements
The settlement landscape in the EpiPen litigation spans multiple tracks, and the numbers are substantial. The largest single settlement was the $345 million agreement Pfizer reached with the plaintiff class in November 2021. Pfizer’s involvement stems from its subsidiary King Pharmaceuticals, which held certain rights related to EpiPen. The Mylan defendants — including Viatris, the company Mylan became after merging with Pfizer’s Upjohn division, and former CEO Heather Bresch — agreed to a $264 million settlement with class plaintiffs. A separate $73.5 million settlement resolved claims brought by direct purchasers, primarily drug wholesalers, for the class period running from March 13, 2014 through February 6, 2025.
At the state level, Indiana Attorney General Todd Rokita announced a $6.25 million settlement from Viatris and Pfizer on February 9, 2026, resolving an antitrust lawsuit his office had filed in early 2025. The Indiana case alleged violations of the Indiana Deceptive Consumer Sales Act, the Indiana Antitrust Act, and the Medicaid False Claims Act. Virginia reached a separate $6.25 million settlement with Viatris, which included commitments to consumer-facing measures such as increased co-pay assistance, though Viatris denied liability in that agreement. Adding these figures together, the total settlement payouts across federal class actions and state actions run well over $600 million. That is a significant sum, though spread across millions of affected consumers, individual payments will vary considerably depending on how many claimants filed, the amount they spent on EpiPen, and the specific settlement fund’s distribution formula.
How to Check Your EpiPen Settlement Claim Status and Redeem Your Payment
If you previously filed a claim in one of the EpiPen class action settlements, now is the time to pay attention to your email and mail. As of February 2026, consumers who filed claims were being notified that it was time to redeem their claims. Redemption is a separate step from filing — it typically requires you to confirm your information and sometimes provide updated payment details so the settlement administrator can process your check or electronic payment. Missing a redemption deadline could mean forfeiting the payment you are otherwise entitled to. The difference between filing a claim and redeeming one trips up many consumers. Filing is the initial step where you submit proof of purchase or other documentation to establish eligibility.
Redemption comes later, often months or years after the settlement receives final court approval, and it is the step where the money actually gets distributed. If you filed a claim and have not heard anything, check the official EpiPen class action settlement website at epipenclassaction.com for updates. For the direct purchaser settlement, the site epipendppsettlement.com has information specific to wholesaler claims. Do not rely on third-party sites for claim status — go directly to the official settlement pages. One practical consideration: if you have moved or changed your email address since filing your claim, update your information with the settlement administrator as soon as possible. Settlement notices are often sent to the address on file, and if yours is outdated, you may miss critical deadlines.
Why the EpiPen Price Increase Became a Symbol of Pharmaceutical Pricing Abuse
The EpiPen controversy stands out even in an industry where price increases are routine. A 600% price increase on a life-saving medication with no real therapeutic alternative is difficult to justify under any framework, and the public backlash that erupted when these increases came to light in 2016 was fierce. Congressional hearings followed. Mylan’s CEO Heather Bresch — who was named personally in the class action settlements — faced withering questioning about the company’s pricing decisions. The company eventually introduced a generic version at a lower price point and expanded its patient assistance programs, but critics argued these were damage-control measures that did not address the underlying market dynamics.
The broader warning here is about the role PBMs play in drug pricing. PBMs were originally created to negotiate lower drug prices on behalf of insurers and consumers. But the EpiPen case illustrates how the rebate system can be turned on its head — where higher list prices benefit PBMs financially, creating a perverse incentive structure that hurts the patients the system was supposed to protect. Even with the partial court dismissal of the PBM-specific claims, the economic reality described in the litigation has fueled ongoing calls for PBM reform at both the state and federal levels. A limitation worth acknowledging: even the combined $600-plus million in settlements represents a fraction of the revenue Mylan earned from EpiPen during the years of price increases. For some consumers and advocates, the settlements feel less like accountability and more like a cost of doing business.
State Attorney General Actions Signal Continued Enforcement Pressure
The 2026 settlements in Indiana and Virginia are notable not just for their dollar amounts but for what they signal about ongoing state-level enforcement. Indiana AG Todd Rokita framed the $6.25 million settlement squarely as a response to putting “profit over patients,” and the lawsuit invoked multiple state statutes including the Medicaid False Claims Act, suggesting the state believed taxpayer-funded programs were also harmed by the alleged price inflation.
Virginia’s settlement, which also totaled $6.25 million, included a commitment from Viatris to increase co-pay assistance for consumers — a forward-looking remedy that goes beyond simple monetary penalties. These state actions can proceed independently of the federal class actions, and they reflect a growing trend of state attorneys general using their antitrust and consumer protection authority to take on pharmaceutical pricing. For consumers in states that have not yet brought their own actions, the Indiana and Virginia outcomes could serve as templates for future enforcement.
What the EpiPen Litigation Means for Future Pharmaceutical Antitrust Cases
The EpiPen litigation has left a complicated legacy for pharmaceutical antitrust law. On one hand, the massive settlements demonstrate that drug companies face real financial consequences when pricing practices cross legal lines. On the other, the court’s dismissal of the PBM rebate theory suggests that proving anticompetitive conduct through the rebate system remains legally difficult, even when the economic harm to consumers is well documented.
Future plaintiffs challenging similar arrangements will need to find legal theories that can survive the scrutiny the EpiPen PBM claims did not. Looking ahead, the EpiPen case has contributed to a broader conversation about pharmaceutical pricing reform that now includes legislative proposals targeting PBM transparency, rebate pass-through requirements, and formulary access standards. Whether those reforms materialize remains uncertain, but the factual record established in the EpiPen litigation — hundreds of pages of evidence about how rebate arrangements can be used to exclude competition — will likely serve as a reference point for policymakers for years to come.
Frequently Asked Questions
How much money will I get from the EpiPen class action settlement?
Individual payment amounts depend on the specific settlement fund, the number of valid claims filed, and how much you spent on EpiPen during the class period. The major settlement funds total over $600 million combined, but divided among millions of potential claimants, individual payments will vary. Check your claim status at epipenclassaction.com for specifics.
What is the deadline to redeem my EpiPen settlement claim?
As of February 2026, consumers who previously filed claims were being notified to redeem them. Deadlines vary by settlement, so check the official settlement website and any correspondence you received from the settlement administrator. If you have moved or changed your email, update your contact information immediately.
Can I still file a new claim in the EpiPen class action?
The filing deadlines for the major federal class action settlements have generally passed. However, state attorney general actions like those in Indiana and Virginia may have separate consumer relief components. Check your state attorney general’s website for any available relief programs.
What did Mylan actually do wrong with EpiPen pricing?
The class action alleged that Mylan inflated EpiPen’s list price by over 600% and paid excessive rebates to pharmacy benefit managers in exchange for keeping EpiPen as the exclusive or preferred option on insurance formularies, effectively blocking cheaper competitors. While Mylan and Viatris denied liability in several settlements, the company agreed to pay hundreds of millions of dollars to resolve the claims.
Who are the defendants in the EpiPen class action?
The primary defendants include Mylan N.V., Mylan Specialty L.P., Mylan Pharmaceuticals Inc., Viatris Inc. (Mylan’s successor company), former CEO Heather Bresch, and Pfizer. Pfizer’s involvement relates to its subsidiary’s historical connection to EpiPen rights.
What is a PBM and why does it matter in this case?
A pharmacy benefit manager (PBM) is a company that manages prescription drug benefits for health insurers. Major PBMs like CVS Caremark, Express Scripts, and OptumRx decide which drugs appear on insurance formularies. The EpiPen case alleged that Mylan used excessive rebate payments to these PBMs to keep competitors off formularies, though a federal court dismissed that specific legal theory while other claims proceeded.